Reactivation of hepatitis B virus after rituximab‐containing treatment in patients with CD20‐positive B‐cell lymphoma

BACKGROUND: Reactivation of hepatitis B virus (HBV) after rituximab‐containing chemotherapy in patients with B‐cell lymphoma has been recognized as a potentially serious complication in HBV immune patients. METHODS: To determine the HBV reactivation in patients treated with rituximab, a retrospectiv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2010-10, Vol.116 (20), p.4769-4776
Hauptverfasser:	Matsue, Kosei, Kimura, Shun‐Ichi, Takanashi, Yoko, Iwama, Kan‐Ichi, Fujiwara, Hideaki, Yamakura, Masayuki, Takeuchi, Masami
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Alanine transaminase Antibodies Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Murine-Derived antibody to hepatitis B core antigen Antigens, CD20 - metabolism B-cell lymphoma Biological and medical sciences Cancer Chemotherapy Complications Cost benefit analysis DNA, Viral - analysis double prime B-cell lymphoma Female Hematologic and hematopoietic diseases hepatitis B Hepatitis B - complications Hepatitis B Antibodies - analysis hepatitis B core antigen Hepatitis B surface antigen Hepatitis B virus Hepatitis B virus - isolation & purification Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Liver lymphoma Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - immunology Lymphoma, B-Cell - virology Male Medical sciences Middle Aged reactivation Retrospective Studies Risk factors Rituximab transaminase Tumors Virus Activation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!